Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 28812

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28812

License Grant
UTRF, the University hereby grants to Irish Licensee: (a) an exclusive (even as to UT and UTRF, subject to any rights expressly reserved in this Agreement), research and commercial right and license in the Field of Use, with the right to grant Sublicenses, under UTRF’s rights in Licensed Patents to practice under the Licensed Patents; and (b) an exclusive (even as to UT and UTRF, subject to any rights expressly reserved in this Agreement), commercial right and license in the Field of Use, with the right to grant Sublicenses, to utilize the Licensed Know-How for the purpose of practicing under the Licensed Patents (collectively, the License).
License Property
Licensed Patents
U.S. Patent Application # 11/966,988, titled Treatment and Prophylaxis of Amyloidosis
PCT International Application No. PCT/US07/089169, titled Treatment and Prophylaxis of Amyloidosis.

In medicine, amyloidosis refers to a variety of conditions wherein normally soluble proteins become insoluble and are deposited in the extracellular space of various organs or tissues, disrupting normal function.

The Licensee jointly own with the Licensor patent applications pending in the United States Australia, Brazil, China, Colombia, Eurasia, Europe, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Mexico, Norway, New Zealand, Philippines, Singapore and South Africa, and have exclusively licensed the joint ownership interest in these patent applications.

Field of Use
Field of Use means any and all diagnostic or therapeutic applications directed toward identification or treatment of disease.

IPSCIO Record ID: 7516

License Grant
The Licensor hereby agrees, unconditionally and irrevocably, that the Licensee shall have the exclusive and unrestricted right worldwide, to exercise, use and commercialize and allow third parties to exercise, use and commercialize the Invention during the Agreed Term.

Invention shall thereafter mean the inventions covered by any claim(s) of a Patent issued or validated in the USA, the United Kingdom, France or Germany and not subsequently invalidated.

License Property
Patent and Patent Applications

Israel Patent Application 123998 (which is priority document for all patents/patent applications listed below)

PCT/IL99/00173 (all patents/patent applications listed below via this application).

Europe   European Patent Application EP 1071702 B1 covering:   Austria Belgium Cyprus Denmark Finland France Germany Greece

Ireland

Italy

Latvia

Lithuania

Luxembourg

Monaco

Netherlands

Portugal

Romania

Slovenia

Spain

Sweden

Switzerland (+Liechtenstein)

United Kingdom

Other European Applications:

Czech Republic
PV 2000-3625

Hungary
P 01 01653

Norway
20004998

Poland
P 343 360

Ukraine
20000095546

Eurasia

Eurasian Application No. 200000888 covering:

Armenia
Azerbaijan
Belarus
Kazakhstan
Kirgizstan
Moldova
Russia
Tajikistan
Turkmenistan

Americas

Brazil
9909908-0

Canada
2,325,933

Mexico
009863

United States  6,395,722(granted), 6,384,024(granted), 10/078,671

Others

Australia
30515/99 (granted)

China
99804903.4

Indonesia
W2000 1998

Japan
2000-543488

New Zealand
507309

South Korea
10-2000-7010903

Turkey
84564

IPSCIO Record ID: 6955

License Grant
The Licensor granted the Licensee an exclusive license to certain patents and patent applications covering certain gel products, including rights to sublicense, in order to develop and market the products in certain territories, including the U.S., Canada, New Zealand, South Africa, Israel, Mexico, China (including Hong Kong) and Indonesia.
License Property
Our products for female sexual health, menopause, contraception and male hypogonadism include our gel formulations of estradiol or testosterone and combinations of estrogen, progestogen and androgen: LibiGel, Elestrin, Bio-T-Gel and Pill-Plus, our triple component contraceptive that uses various combinations of estrogens, progestogens and androgens in development for the treatment of FSD in women using oral or transdermal contraceptives.
Field of Use
The rights granted apply to the healthcare for women.

The Licensee is the exclusive licensee in certain territories for issued U.S. patents for these products and additional patent applications have been filed for this licensed technology in the U.S. and several foreign jurisdictions.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.